These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26285615)

  • 21. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
    Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia.
    Small S
    Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628
    [No Abstract]   [Full Text] [Related]  

  • 24. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
    Bourrier N; Landego I; Bucher O; Squires M; Streu E; Hibbert I; Whiteside T; Gibson SB; Geirnaert M; Johnston JB; Dawe DE; Banerji V
    BMC Cancer; 2022 Feb; 22(1):148. PubMed ID: 35123433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.
    Freeman CL; Morschhauser F; Sehn L; Dixon M; Houghton R; Lamy T; Fingerle-Rowson G; Wassner-Fritsch E; Gribben JG; Hallek M; Salles G; Cartron G
    Blood; 2015 Dec; 126(24):2646-9. PubMed ID: 26447188
    [No Abstract]   [Full Text] [Related]  

  • 27. Obinutuzumab in hematologic malignancies: lessons learned to date.
    Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
    Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
    Said R; Tsimberidou AM
    Expert Opin Biol Ther; 2017 Nov; 17(11):1463-1470. PubMed ID: 28893099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
    Robak T; Blonski JZ; Robak P
    Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab.
    Reslan L; Dalle S; Herveau S; Perrial E; Dumontet C
    Leuk Lymphoma; 2014 Jan; 55(1):188-90. PubMed ID: 23537278
    [No Abstract]   [Full Text] [Related]  

  • 33. Obinutuzumab for the treatment of indolent lymphoma.
    Edelmann J; Gribben JG
    Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 2015].
    Obrtlíková P; Urbanová R
    Klin Onkol; 2015; 28 Suppl 3():3S22-9. PubMed ID: 26489498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
    Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y
    Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obinutuzumab: the more the merrier?
    Burger JA
    Blood; 2016 Jan; 127(1):6-8. PubMed ID: 26744434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.
    Russell A; Yaraskavitch M; Fok D; Chhibber S; Street L; Korngut L
    J Neuromuscul Dis; 2017; 4(3):251-257. PubMed ID: 28869483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.
    Sirard C; Trehu EG
    J Clin Oncol; 2008 May; 26(14):2411-2; author reply 2412-3. PubMed ID: 18467736
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of obinutuzumab in chronic lymphocytic leukemia.
    Wierda W
    Clin Adv Hematol Oncol; 2014 Jun; 12(6):395-7. PubMed ID: 25003571
    [No Abstract]   [Full Text] [Related]  

  • 40. Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy.
    Traynor K
    Am J Health Syst Pharm; 2013 Dec; 70(24):2162. PubMed ID: 24296835
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.